(Total Views: 105)
Posted On: 10/22/2024 4:47:03 PM
Post# of 124
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Key Alzheimer’s Research at CTAD Conference in Madrid
Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid from Oct. 29 to Nov. 1, 2024. The company will present two posters highlighting Buntanetap’s efficacy in early Alzheimer’s patients and its impact on reducing neurotoxic proteins, improving axonal integrity, and enhancing neuronal function. These results further support Annovis Bio’s ongoing efforts to develop transformative therapies for neurodegenerative diseases.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid from Oct. 29 to Nov. 1, 2024. The company will present two posters highlighting Buntanetap’s efficacy in early Alzheimer’s patients and its impact on reducing neurotoxic proteins, improving axonal integrity, and enhancing neuronal function. These results further support Annovis Bio’s ongoing efforts to develop transformative therapies for neurodegenerative diseases.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
